Medeon BiodesignROCO:6499 68 Current Ratio is 8.21 as of Dec. 2025, which is 22% below its 10-year median of 10.53. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.08 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 855 Medical Devices & Instruments companies, Medeon Biodesign ranks better than 89.59% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Medeon Biodesign's current ratio for the quarter that ended in Dec. 2025 was 8.21.
Medeon Biodesign has a current ratio of 8.21. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Medeon Biodesign's Current Ratio or its related term are showing as below:
ROCO:6499'
s Current Ratio Range Over the Past 10 Years
Min: 6.11 Med: 10.53 Max: 14.91
Current: 8.21
During the past 13 years, Medeon Biodesign's highest Current Ratio was 14.91. The lowest was 6.11. And the median was 10.53.
ROCO:6499's Current Ratio is ranked better than 89.59% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 2.5
vs ROCO:6499: 8.21
Medeon Biodesign (ROCO:6499) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Medeon Biodesign Current Ratio Related Terms
Medeon Biodesign Current Ratio Historical Data
* Premium members only.
The historical data trend for Medeon Biodesign's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6499 vs ISRG, BDX, MDLN: Current Ratio Comparison
For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeon Biodesign Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Current Ratio distribution charts can be found below:
* The bar in red indicates where Medeon Biodesign's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medeon Biodesign (ROCO:6499) has a Current Ratio of 8.21 as of Dec. 2025. This is 22% below median its historical median of 10.53. Over the past decade, Medeon Biodesign's Current Ratio has ranged from 6.11 to 14.91. According to the industry distribution chart, Medeon Biodesign ranks #89 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 10.4%.
Is Medeon Biodesign's Current Ratio too high?
Medeon Biodesign's current Current Ratio of 8.21 is 22% below median its 10-year median of 10.53. Over the past 10 years, this metric has ranged from a low of 6.11 to a high of 14.91. The Medical Devices & Instruments industry median Current Ratio is 2.50. Medeon Biodesign's value of 8.21 is 228.4% above this industry median. Based on the distribution chart, Medeon Biodesign ranks #89 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Current Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Medeon Biodesign ranks #89 out of 855 companies for Current Ratio. This places Medeon Biodesign in the top 10% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.50. Medeon Biodesign's value of 8.21 is 228.4% above this benchmark. Historically, Medeon Biodesign's own Current Ratio has ranged from 6.11 to 14.91 over the past decade. While the company's 10-year median is 10.53 vs. the industry median of 2.50, Medeon Biodesign has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.50, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeon Biodesign's current Current Ratio of 8.21 is 228.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current Current Ratio is 8.21, which is 22% below median its own 10-year median of 10.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.08, compared to a current price of NT$71.00 — trading 33.7% below its estimated fair value. The current Current Ratio is 8.21, which is 22% below median its 10-year median of 10.53 and 228.4% above the Medical Devices & Instruments industry median of 2.50. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Current Ratio is 8.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?
Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued.
The current stock price of NT$71.00 is trading 33.7% below its estimated GF Value™ of NT$107.08.
GuruFocus considers Medeon Biodesign to be Significantly Undervalued.
Key valuation signals for ROCO:6499:
Current Ratio: 8.21 (22% below median its 10-year median of 10.53)
GF Value™: NT$107.08 vs. price of NT$71.00 (33.7% below fair value)
Industry Position: 228.4% above the Medical Devices & Instruments median (#89 of 855)
No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
68GF Score
Get the complete analysis for ROCO:6499
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6499 has been successfully added to your 
